Today Biogen
Idec BIIB and Swedish
Orphan Biovitrum AB (publ) (Sobi) SOBI announced that the
detailed phase 3 data for the companies' investigational long-lasting
recombinant factor VIII Fc fusion protein candidate ELOCTATE™ were
published online in Blood, the journal of the American Society of
Hematology (ASH). Results from the A-LONG study showed that people with
severe hemophilia A may achieve effective prevention or reduction of
bleeding episodes with one or two prophylactic infusions a week.
ELOCTATE uses a technology called Fc fusion to prolong the time the
therapy circulates in the body, which may extend the time between
prophylactic infusions. If approved, ELOCTATE may enable people with
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in